The FDA has approved Mimrylo (rusfertide) — a first-of-its-kind therapy for polycythemia vera (PV), a rare blood cancer in which the body makes too many red blood cells, thickening the blood and raising the risk of clots.
Mimrylo works by mimicking hepcidin, the hormone that naturally regulates iron in the body. By limiting the iron available to make new red blood cells, it curbs their overproduction and helps keep blood counts under control — a novel mechanism for the disease.
What the trial showed
Many PV patients rely on repeated phlebotomies (therapeutic blood draws) to manage their counts. In the pivotal trial, 76.9% of patients on Mimrylo required no phlebotomies over 32 weeks, versus 32.9% on placebo — a substantial reduction in the need for that ongoing procedure.
Why it matters
Polycythemia vera is a chronic myeloproliferative neoplasm that often requires lifelong management. A therapy that directly addresses the iron-driven overproduction of red cells — and spares patients frequent blood draws — offers a meaningfully different approach for a condition where options have been limited.